# EDGAR Filing Document

**Accession Number:** 0001705162
**File Stem:** 0001140361-23-010678
**Filing Date:** 2023-3
**Character Count:** 17285
**Document Hash:** f87c92a0d85fe6cf23eae5d7284ee4cf
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-23-010678.hdr.sgml**: 20230308

**ACCESSION NUMBER**: 0001140361-23-010678

**CONFORMED SUBMISSION TYPE**: SC 13G/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230308

**DATE AS OF CHANGE**: 20230308

**GROUP MEMBERS**: INTERMEDIATE CAPITAL INVESTMENTS LTD

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Eliem Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001768446
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 832273741
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92797
- **FILM NUMBER:** 23716073

**BUSINESS ADDRESS:**
- **STREET 1:** 23515 NE NOVELTY HILL ROAD
- **STREET 2:** SUITE B221 #125
- **CITY:** REDMOND
- **STATE:** WA
- **ZIP:** 98053
- **BUSINESS PHONE:** 425-276-2300

**MAIL ADDRESS:**
- **STREET 1:** 23515 NE NOVELTY HILL ROAD
- **STREET 2:** SUITE B221 #125
- **CITY:** REDMOND
- **STATE:** WA
- **ZIP:** 98053
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Intermediate Capital Group plc
- **CENTRAL INDEX KEY:** 0001705162
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A

**BUSINESS ADDRESS:**
- **STREET 1:** JUXON HOUSE
- **STREET 2:** 100 ST. PAUL'S CHURCHYARD
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** EC4M 8BU
- **BUSINESS PHONE:** 0044 203  201 7700

**MAIL ADDRESS:**
- **STREET 1:** JUXON HOUSE
- **STREET 2:** 100 ST. PAUL'S CHURCHYARD
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** EC4M 8BU

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

#### <br>

------

### SCHEDULE 13G

#### UNDER THE SECURITIES EXCHANGE ACT OF 1934

#### (Amendment No. 1)\*

------

#### <br>

## Eliem Therapeutics, Inc.

#### (Name of Issuer)

------

#### Common Stock, $0.0001 par value per share

#### (Title of Class of Securities)

#### 28658R106

#### (CUSIP Number)

#### December 31, 2022

#### (Date of Event Which Requires Filing of this Statement)

------

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☑ Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

------

---

| | | |
|:---|:---|:---|
| **CUSIP No. 28658R106** | **SCHEDULE 13G** | **Page 2 of 6 Pages** |

---

---

| | | |
|:---|:---|:---|
| **1** | **NAMES OF REPORTING PERSONS** | **NAMES OF REPORTING PERSONS** |
| **1** | **Intermediate Capital Investments Limited** | **Intermediate Capital Investments Limited** |
| **1** | **Intermediate Capital Investments Limited** | **Intermediate Capital Investments Limited** |
| **2** | **CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP** | **CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP** |
| **2** | (a)☐ | (a)☐ |
| **2** | (b)☒ | (b)☒ |
| **3** | **SEC USE ONLY** | **SEC USE ONLY** |
| **3** |  |  |
| **3** |  |  |
| **4** | **CITIZENSHIP OR PLACE OF ORGANIZATION** | **CITIZENSHIP OR PLACE OF ORGANIZATION** |
| **4** | United Kingdom | United Kingdom |
| **4** | United Kingdom | United Kingdom |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **5** | **SOLE VOTING POWER** |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **5** | 0 |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **5** | 0 |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **6** | **SHARED VOTING POWER** |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **6** | 2002563 |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **6** | 2002563 |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **7** | **SOLE DISPOSITIVE POWER** |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **7** | 0 |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **7** | 0 |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **8** | **SHARED DISPOSITIVE POWER** |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **8** | 2002563 |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **8** | 2002563 |
| **9** | **AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON** | **AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON** |
| **9** | 2002563 | 2002563 |
| **9** | 2002563 | 2002563 |
| **10** | **CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)** | **CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)** |
| **10** | ☐ | ☐ |
| **10** | ☐ | ☐ |
| **11** | **PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)** | **PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)** |
| **11** | 7.5% (1) | 7.5% (1) |
| **11** | 7.5% (1) | 7.5% (1) |
| **12** | **TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)** | **TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)** |
| **12** | CO | CO |
| **12** | CO | CO |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) The percentage of class was calculated based on 26,567,681 shares of Common Stock outstanding as of November 10, 2022, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on
 November 14, 2022.

------

---

| | | |
|:---|:---|:---|
| **CUSIP No. 28658R106** | **SCHEDULE 13G** | **Page 3 of 6 Pages** |

---

---

| | | |
|:---|:---|:---|
| **1** | **NAMES OF REPORTING PERSONS** | **NAMES OF REPORTING PERSONS** |
| **1** | **Intermediate Capital Group plc** | **Intermediate Capital Group plc** |
| **1** | **Intermediate Capital Group plc** | **Intermediate Capital Group plc** |
| **2** | **CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP** | **CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP** |
| **2** | (a)☐ | (a)☐ |
| **2** | (b)☒ | (b)☒ |
| **3** | **SEC USE ONLY** | **SEC USE ONLY** |
| **3** |  |  |
| **3** |  |  |
| **4** | **CITIZENSHIP OR PLACE OF ORGANIZATION** | **CITIZENSHIP OR PLACE OF ORGANIZATION** |
| **4** | United Kingdom | United Kingdom |
| **4** | United Kingdom | United Kingdom |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **5** | **SOLE VOTING POWER** |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **5** | 0 |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **5** | 0 |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **6** | **SHARED VOTING POWER** |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **6** | 2002563 |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **6** | 2002563 |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **7** | **SOLE DISPOSITIVE POWER** |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **7** | 0 |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **7** | 0 |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **8** | **SHARED DISPOSITIVE POWER** |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **8** | 2002563 |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **8** | 2002563 |
| **9** | **AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON** | **AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON** |
| **9** | 2002563 | 2002563 |
| **9** | 2002563 | 2002563 |
| **10** | **CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)** | **CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)** |
| **10** | ☐ | ☐ |
| **10** | ☐ | ☐ |
| **11** | **PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)** | **PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)** |
| **11** | 7.5% (1) | 7.5% (1) |
| **11** | 7.5% (1) | 7.5% (1) |
| **12** | **TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)** | **TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)** |
| **12** | CO | CO |
| **12** | CO | CO |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The percentage of class was calculated based on 26,567,681 shares of Common Stock outstanding as of November 10, 2022, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on
 November 14, 2022.

------

---

| | | |
|:---|:---|:---|
| **CUSIP No. 28658R106** | **SCHEDULE 13G** | **Page 4 of 6 Pages** |

---

**Item 1.** **Issuer**<br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Name of Issuer:

Eliem Therapeutics, Inc. (the "**<u>Issuer</u>**")

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Address of Issuer's Principal Executive Offices:

23515 NE Novelty Hill Road, Suite B221 #125

Redmond, WA 98053

**Item 2.** **Filing Person**<br>

(a) – (c) Name of Persons Filing; Address; Citizenship:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Intermediate Capital Investments Limited ("ICIL"), a United Kingdom private limited company; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Intermediate Capital Group plc ("ICG plc"), a United Kingdom premium limited company.

ICG plc is the sole shareholder of ICIL. The address of the principal business office of each Reporting Person is Procession House, 55 Ludgate Hill, London EC4M 7JW.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Title of Class of Securities:

Common Stock, par value $0.0001 per share

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) CUSIP Number:

28658R106

**Item 3.** **If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:**<br>

(a) ☐ Broker or dealer registered under Section 15 of the Act;

(b) ☐ Bank as defined in Section 3(a)(6) of the Act;

(c) ☐ Insurance company as defined in Section 3(a)(19) of the Act;

(d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940;

(e) ☐ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

(f) ☐ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

(g) ☐ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

(h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;

(j) ☐ A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);

(k) ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

------

---

| | | |
|:---|:---|:---|
| **CUSIP No. 28658R106** | **SCHEDULE 13G** | **Page 5 of 6 Pages** |

---

---

| | |
|:---|:---|
| **Item 4.** | **Ownership.** |

---

---

| | |
|:---|:---|
| (a) and (b) | Amount beneficially owned: |

---

ICIL directly owns 2,002,563 shares of Common Stock, which represents approximately 7.5% of the outstanding Common Stock of the Issuer. ICG plc may be deemed to beneficially own the shares of Common Stock held directly by ICIL.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Number of shares as to which such person has:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | &nbsp;&nbsp;&nbsp; **Number of Shares of Common Stock** | &nbsp;&nbsp;&nbsp; **Number of Shares of Common Stock** | &nbsp;&nbsp;&nbsp; **Number of Shares of Common Stock** | &nbsp;&nbsp;&nbsp; **Number of Shares of Common Stock** | &nbsp;&nbsp;&nbsp; **Number of Shares of Common Stock** | &nbsp;&nbsp;&nbsp; **Number of Shares of Common Stock** | &nbsp;&nbsp;&nbsp; **Number of Shares of Common Stock** | &nbsp;&nbsp;&nbsp; **Number of Shares of Common Stock** |
| **Reporting Person** | &nbsp;&nbsp;&nbsp;&nbsp;(i) | &nbsp;&nbsp;&nbsp;&nbsp;(i) | &nbsp;&nbsp;&nbsp;&nbsp;(ii) | &nbsp;&nbsp;&nbsp;&nbsp;(ii) | &nbsp;&nbsp;&nbsp;&nbsp;(iii) | &nbsp;&nbsp;&nbsp;&nbsp;(iii) | &nbsp;&nbsp;&nbsp;&nbsp;(iv) | &nbsp;&nbsp;&nbsp;&nbsp;(iv) |
| ICIL |  | 0 |  | 2,002,563 |  | 0 |  | 2,002,563 |
| ICG plc |  | 0 |  | 2,002,563 |  | 0 |  | 2,002,563 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Sole power to vote or direct the vote

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Shared power to vote or to direct the vote

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Sole power to dispose or to direct the disposition of

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Shared power to dispose or to direct the disposition of

The percentage of class was calculated based on 26,567,681 shares of Common Stock outstanding as of November 10, 2022, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2022.

**Item 5.** **Ownership of Five Percent or Less of a Class.**<br>

Not applicable.

**Item 6.** **Ownership of More than Five Percent on Behalf of Another Person.**<br>

Not applicable.

**Item 7.** **Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.**<br>

Not applicable.

**Item 8.** **Identification and Classification of Members of the Group.**<br>

Not applicable.

**Item 9.** **Notice of Dissolution of Group.**<br>

Not applicable.

**Item 10.** **Certification.**<br>

Not applicable.

------

---

| | | |
|:---|:---|:---|
| **CUSIP No. 28658R106** | **SCHEDULE 13G** | **Page 6 of 6 Pages** |

---

#### SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: March 8, 2023

---

| | |
|:---|:---|
| **INTERMEDIATE CAPITAL INVESTMENTS LIMITED** | **INTERMEDIATE CAPITAL INVESTMENTS LIMITED** |
| By: | /s/ Andrew Lewis |
| Name: Andrew Lewis | Name: Andrew Lewis |
| Title: Company Secretary | Title: Company Secretary |

---

---

| | |
|:---|:---|
| **INTERMEDIATE CAPITAL GROUP PLC** | **INTERMEDIATE CAPITAL GROUP PLC** |
| By: | /s/ Andrew Lewis |
| Name: Andrew Lewis | Name: Andrew Lewis |
| Title: Company Secretary | Title: Company Secretary |

---

------

#### EXHIBIT INDEX

<u>Exhibit</u> <br>[99.1](brhc10049483_ex99-1.htm) Joint Filing Statement

------

## Exhibit 99.1

------

#### EXHIBIT 99.1

#### <br>

#### Joint Filing Agreement

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.

Date: March 8, 2023

---

| | |
|:---|:---|
| **INTERMEDIATE CAPITAL INVESTMENTS LIMITED** | **INTERMEDIATE CAPITAL INVESTMENTS LIMITED** |
| By: | /s/ Andrew Lewis |
| Name: Andrew Lewis | Name: Andrew Lewis |
| Title: Company Secretary | Title: Company Secretary |

---

---

| | |
|:---|:---|
| **INTERMEDIATE CAPITAL GROUP PLC** | **INTERMEDIATE CAPITAL GROUP PLC** |
| By: | /s/ Andrew Lewis |
| Name: Andrew Lewis | Name: Andrew Lewis |
| Title: Company Secretary | Title: Company Secretary |

---

------